Navigation Links
Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Date:5/8/2009

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the following investor conferences:

Bank of America and Merrill Lynch 2009 Health Care Conference

    Date:  Tuesday, May 12, 2009
    Time:  2:40 p.m. - 3:10 p.m. Eastern
    Location: The New York Palace Hotel, New York
    Speaker: Michael Narachi, Chief Executive Officer

Canaccord Adams Diabetes and Obesity Conference

    Date:  Tuesday, May 12, 2009
    Time:  10:40 a.m. - 11:10 a.m. Eastern
    Location: InterContinental The Barclay New York, New York
    Speaker: Graham Cooper, Chief Financial Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood Registry® ... of the 10th Annual World Stem Cell Summit, the largest ... The 2014 World Stem Cell Summit will be held December ... Texas . The World Stem ... of lifesaving cures and therapies, convening the most prominent figures ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... Empowers Users to Take Full Control of the ... to Results Disclosure - while Adhering to Changing ... to Manage Their Clinical Trial Registration and Results ... ( http://www.intrasphere.com ), a ...
... , - European Operating ... Healthcare Educational Program, Accepted,for Accreditation , ... healthcare barrier,protective solutions, has announced it has taken a ... the area of continued,education. , ...
... developed an entirely new method for starting chemical reactions. ... control catalytic activity one of the most fundamental ... reactions with mechanical force. This discovery paves the way ... influence of mechanical tension. The results of their research ...
Cached Biology Technology:Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4A molecular ripcord for chemical reactions 2
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... November 2014)—In support of a bold quest to rid ... Gates Foundation today announced an award of US$156 million ... (MVI) in building new vaccines that will interrupt the ... "accelerating to zero" agenda. Such vaccines would ensure that ... called an "immunological bed net." , This approach ...
(Date:11/2/2014)... walk into a bar and bump into a biologist . ... to some late-night nerd sketch, researchers have taken this premise ... biology, namely, finding meaning in the rising oceans of genomic ... cancer mutations that genome-wide studies are publishing at a dizzying ... parse the signal from the noise (and there is no ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... of some insects or the deep black of a ... the nanostructure of a fly,s eyes, according to Penn ... and inexpensively copy biological surface structures. "Only a ... says Akhlesh Lakhtakia, the Charles Godfrey Binder (Endowed) Professor ...
... size guidelines for all-terrain vehicles (ATV) are inadequate to ... results from a study by researchers at the University ... found that national ATV size guidelines for youth ... frame or engine size do not assure a ...
... of sedentary and overweight older people placed on a four-month ... more fat, compared to older sedentary people who were placed ... study also showed that when older people diet without exercising, ... said senior researcher Bret H. Goodpaster. When they combined weight ...
Cached Biology News:Coating copies microscopic biological surfaces 2Coating copies microscopic biological surfaces 3Study finds ATV guidelines inadequate 2Older people who diet without exercising lose valuable muscle mass 2
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
... Silver Staining Kit is uniquely formulated ... with minimal protein modification for optimal ... problems associated with traditional silver stains ... because the reagents used do not ...
...
Biology Products: